What is FNP-223 used for?

FNP-223 is indicated for Relapsing forms of multiple sclerosis.

FNP-223 is developed by Ferrer Internacional S.A..

What are the side effects of FNP-223?

Common side effects include Headache, Nausea, Diarrhea.

Last reviewed 2026-04-23 · How we verify

FNP-223

Ferrer Internacional S.A. · Phase 2 active Small molecule

FNP-223 is a small molecule that targets the S1P1 receptor.

FNP-223 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.

At a glance

Generic name	FNP-223
Sponsor	Ferrer Internacional S.A.
Drug class	S1P1 receptor modulator
Target	S1P1
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

By binding to the S1P1 receptor, FNP-223 aims to modulate sphingosine-1-phosphate signaling, which plays a crucial role in various cellular processes, including immune cell trafficking and lymphocyte egress from lymphoid organs.

Approved indications

Relapsing forms of multiple sclerosis

Common side effects

Headache
Nausea
Diarrhea

Key clinical trials

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FNP-223 CI brief — competitive landscape report
FNP-223 updates RSS · CI watch RSS
Ferrer Internacional S.A. portfolio CI